Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip E Tarr

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
F1000 Medicine Reports|December 21, 2010
Genetic screening for metabolic and age-related complications in HIV-infected personsPhilip E Tarr, Amalio Telenti
The Lancet. HIV|April 19, 2017
Another statin option in HIVPhilip E Tarr, Helen Kovari
The Lancet. HIV|September 28, 2018
Anti-inflammatory therapy in well controlled HIV infectionPhilip E Tarr, Alexandra Calmy
The Lancet. HIV|March 30, 2018
Will NNRTIs be driving forward again?Alexandra Calmy, Philip E Tarr
Antiviral Therapy|November 21, 2007
Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complicationsPhilip E Tarr, Amalio Telenti
Current Opinion in HIV and AIDS|January 8, 2015
Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesDavid W Haas, Philip E Tarr
Pharmacogenomics|March 31, 2010
Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomicsPhilip E Tarr, Margalida Rotger, Amalio Telenti
Expert Opinion on Pharmacotherapy|August 10, 2005
Treatment of dyslipidaemia in HIV-infected personsOriol Manuel, Rodolphe Thiébaut, Roger Darioli, et al.
Archives of Internal Medicine|February 11, 2009
Peritoneal tuberculosis after imatinib therapyLaurence Senn, Tibor Kovacsovics, Philip E Tarr, et al.
Journal of Clinical Medicine|February 23, 2020
Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the LiteratureIris Najjar, Florina Paluca, Konstantinos Loukidis, et al.
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
F1000 Medicine Reports|December 21, 2010
Genetic screening for metabolic and age-related complications in HIV-infected personsPhilip E Tarr, Amalio Telenti
The Lancet. HIV|April 19, 2017
Another statin option in HIVPhilip E Tarr, Helen Kovari
The Lancet. HIV|September 28, 2018
Anti-inflammatory therapy in well controlled HIV infectionPhilip E Tarr, Alexandra Calmy
The Lancet. HIV|March 30, 2018
Will NNRTIs be driving forward again?Alexandra Calmy, Philip E Tarr
Antiviral Therapy|November 21, 2007
Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complicationsPhilip E Tarr, Amalio Telenti
Current Opinion in HIV and AIDS|January 8, 2015
Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesDavid W Haas, Philip E Tarr
Pharmacogenomics|March 31, 2010
Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomicsPhilip E Tarr, Margalida Rotger, Amalio Telenti
Expert Opinion on Pharmacotherapy|August 10, 2005
Treatment of dyslipidaemia in HIV-infected personsOriol Manuel, Rodolphe Thiébaut, Roger Darioli, et al.
Archives of Internal Medicine|February 11, 2009
Peritoneal tuberculosis after imatinib therapyLaurence Senn, Tibor Kovacsovics, Philip E Tarr, et al.
Journal of Clinical Medicine|February 23, 2020
Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the LiteratureIris Najjar, Florina Paluca, Konstantinos Loukidis, et al.
Pageof 12